Geneos Wealth Management Inc. Cuts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Geneos Wealth Management Inc. lessened its stake in Moderna, Inc. (NASDAQ:MRNAFree Report) by 14.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,719 shares of the company’s stock after selling 284 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Moderna were worth $171,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. ICA Group Wealth Management LLC acquired a new position in shares of Moderna during the 4th quarter worth about $27,000. First Pacific Financial acquired a new stake in shares of Moderna in the third quarter worth approximately $27,000. Stonebridge Capital Advisors LLC raised its stake in Moderna by 79.1% in the 1st quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock valued at $49,000 after purchasing an additional 125 shares during the last quarter. Arlington Trust Co LLC lifted its holdings in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares in the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in Moderna by 173.5% during the 1st quarter. Parkside Financial Bank & Trust now owns 309 shares of the company’s stock worth $53,000 after purchasing an additional 196 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $105.14 on Monday. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $163.24. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average is $99.86 and its two-hundred day moving average is $93.53.

Moderna (NASDAQ:MRNAGet Free Report) last announced its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same period in the prior year, the firm earned $3.61 EPS. The firm’s revenue for the quarter was down 44.9% on a year-over-year basis. Analysts anticipate that Moderna, Inc. will post -7.48 EPS for the current year.

Insider Activity at Moderna

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total value of $1,635,900.00. Following the sale, the director now owns 2,101,931 shares of the company’s stock, valued at approximately $229,236,594.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO James M. Mock sold 705 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a total transaction of $71,860.65. Following the completion of the transaction, the chief financial officer now owns 5,048 shares in the company, valued at $514,542.64. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00. Following the completion of the sale, the director now owns 2,101,931 shares in the company, valued at $229,236,594.86. The disclosure for this sale can be found here. Over the last three months, insiders sold 94,954 shares of company stock worth $9,966,476. Company insiders own 15.20% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on MRNA shares. Royal Bank of Canada reissued an “outperform” rating and issued a $125.00 price target on shares of Moderna in a research note on Thursday, March 28th. HSBC reissued a “reduce” rating and set a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target on the stock in a report on Tuesday, January 2nd. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Thursday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $126.49.

Read Our Latest Report on Moderna

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Recommended Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.